Charles T. Spencer to Mycobacterium tuberculosis
This is a "connection" page, showing publications Charles T. Spencer has written about Mycobacterium tuberculosis.
Connection Strength
0.421
-
Sefat KMSR, Kumar M, Kehl S, Kulkarni R, Leekha A, Paniagua MM, Ackart DF, Jones N, Spencer C, Podell BK, Ouellet H, Varadarajan N. An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 2024 09 17; 42(22):125909.
Score: 0.196
-
Xia M, Hesser DC, De P, Sakala IG, Spencer CT, Kirkwood JS, Abate G, Chatterjee D, Dobos KM, Hoft DF. A Subset of Protective ?9d2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components. Infect Immun. 2016 09; 84(9):2449-62.
Score: 0.115
-
Abate G, Spencer CT, Hamzabegovic F, Blazevic A, Xia M, Hoft DF. Mycobacterium-Specific ?9d2 T Cells Mediate Both Pathogen-Inhibitory and CD40 Ligand-Dependent Antigen Presentation Effects Important for Tuberculosis Immunity. Infect Immun. 2016 02; 84(2):580-9.
Score: 0.110